Gilead Sciences (GILD) 87.21 $GILD
Last Month's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 7:00AM CST
Source: Unsplash via Pixabay. February proved to be another roller-coaster month for investors. The S&P 500 cratered in the first few trading days of the month, shedding more than 5.5% of its value at its lowest point, but then it came...
AGN: 288.67 (-0.95), GILD: 87.21 (-0.62), XLV: 67.41 (-0.16)
Facebook, Starbucks, Schlumberger Lead Week’s Insider Trades
at Investor's Business Daily - Fri Mar 04, 5:15PM CST
Top brass from Facebook (FB), Starbucks (SBUX), Schlumberger (SLB) and Antero Resources (AR) were among those who made notable insider trades disclosed this week. Facebook Chris Cox, the social media giant's chief product officer, has sold 15,600...
SBUX: 58.70 (-0.34), AR: 22.89 (-1.00), GILD: 87.21 (-0.62), FB: 108.39 (-1.19), PANW: 150.97 (-1.05), SLB: 74.83 (-0.02)
Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
Business Wire - Fri Mar 04, 5:00PM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has elected to settle its conversion obligations in connection with any 1.625% Senior Convertible Notes due 2016 (the "Notes"
submitted for conversion on or after February 1, 2016 entirely in cash.
GILD: 87.21 (-0.62), WFC: 50.11 (+0.34)
Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
Business Wire - Fri Mar 04, 3:00PM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 36th Annual Health Care Conference in Boston.
GILD: 87.21 (-0.62)
What Does Trump's Healthcare Plan Mean for Investors?
Arpita Dutt - Zacks Investment Research - Fri Mar 04, 10:57AM CST
The pharma industry has always stood strongly against attempts to legalize drug re-importation.
BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14), REGN: 403.82 (+1.88)
Another Threat To Gilead's HCV Prices Has Emerged
Shock Exchange - Seeking Alpha - Fri Mar 04, 6:40AM CST
(click to enlarge) NY Attorney General Eric Schneiderman. Source: NY Daily News From Hillary Clinton to Bernie Sanders, politicians brought up the issue of price-gouging by pharmaceutical companies. Many have been reacting to complaints by...
GILD: 87.21 (-0.62)
Gilead: Why The HCV Bull Case Is Bull
Bryan Boulden - at Seeking Alpha - Thu Mar 03, 8:37AM CST
GILD: 87.21 (-0.62)
Chronic Stable Angina Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Gilead Sciences, Lacer, Tasly Pharmaceuticals - Research and Markets
Business Wire - Thu Mar 03, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/23w5kc/chronic_stable) has announced the addition of the "Chronic Stable Angina Global Clinical Trials Review, H1, 2016" report to their offering. The clinical trial report, Chronic Stable Angina Global Clinical Trials Review, H1, 2016" provides an overview of Chronic Stable Angina clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Stable Angina. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered:
GILD: 87.21 (-0.62)
The Zacks Analyst Blog Highlights: Gilead, Amgen, Baxalta, PTC Therapeutics and Cara Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead, Amgen, Baxalta, PTC Therapeutics and Cara Therapeutics
CARA: 5.39 (-0.25), GILD: 87.21 (-0.62), PTCT: 6.06 (-0.04), AMGN: 145.98 (+0.14), BXLT: 39.47 (+0.17)
Dividend Growth Portfolio: February Update
The Dividend Bro - at Seeking Alpha - Thu Mar 03, 7:57AM CST
MMM: 160.07 (+0.69), GE: 30.46 (+0.24), XOM: 82.29 (-0.11), O: 58.16 (-0.86), VTR: 56.75 (+0.04), LUV: 41.50 (-0.53), PEP: 100.00 (+0.84), SBUX: 58.70 (-0.34), T: 37.93 (-0.06), JNJ: 106.50 (-0.15), V: 73.90 (-0.01), JPM: 60.05 (+0.09), TGT: 81.13 (+1.42), ABBV: 56.15 (+0.22), MSFT: 52.03 (-0.32), AAPL: 103.01 (+1.51), CSCO: 26.80 (-0.07), MA: 90.05 (+0.31), KO: 44.11 (+0.15), COP: 41.12 (+2.56), MO: 62.98 (+0.75), BA: 121.07 (+1.46), PM: 94.49 (+1.23), GILD: 87.21 (-0.62), CVS: 99.28 (-0.10), PE: 19.50 (+0.97), PG: 83.49 (+0.65), CVX: 87.93 (+0.40), VZ: 51.81 (-0.08), GIS: 60.20 (+0.41), AFL: 61.03 (+0.05)
Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in Immuno-Oncology Deal
Arpita Dutt - Zacks Investment Research - Wed Mar 02, 1:35PM CST
Major biotech stocks were up last week while companies like Gilead (GILD) provided positive regulatory updates.
CARA: 5.39 (-0.25), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), ALXN: 144.46 (-1.39), PTCT: 6.06 (-0.04), AMGN: 145.98 (+0.14), BXLT: 39.47 (+0.17)
Q4 2015 Earnings Season Review - The Corporate Revenue Recession Deepens
ESTMZ - Wed Mar 02, 11:32AM CST
The fourth quarter earnings season for S&P 500 companies is officially wrapping up. The season started out on a sour note in January, with turbulent US markets, currency headwinds, plunging oil prices and a weakening Chinese economy all plaguing...
SPY: 200.43 (+0.65), GILD: 87.21 (-0.62), FB: 108.39 (-1.19), GOOGL: 730.22 (-1.37)
Biogen and Other Biotech Stocks Are About to Rally, These 3 Charts Show
at The Street - Sun Feb 21, 2:05PM CST
Biotech stocks have been hit hard since last summer, but comprehensive technical analysis shows they'll bounce soon. Here's how you can profit.
BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Is Big Pharma Evil?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Feb 21, 1:06PM CST
Big Pharma has been making a lot of unfortunate headlines lately, especially after Turing Pharmaceuticals' debacle surrounding pricing of Daraprim. Having once been a reasonably respected sector, recent studies have shown that in America, pharma is...
JNJ: 106.50 (-0.15), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Better Buy: Gilead Sciences Inc. vs. Amgen Inc.
Brian Feroldi, The Motley Fool - Motley Fool - Sun Feb 21, 9:04AM CST
Photo by Ano Lobb / Flickr Creative Commons. Gilead Sciences and Amgen have both been stellar investments for their long-term shareholders. Each has put up returns that have utterly smashed the S&P 500 over the past five, 10, and 20...
GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14)
5 Ways to Spot Awe-Inspiring Growth Stocks
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 5:01PM CST
SOURCE: FLICKR USER TAXCREDITS.NET. The never-ending quest of growth investors is to find and invest in revolutionary companies early on, but because there are thousands of publicly traded companies to choose from, it can be pretty tough figuring...
SBUX: 58.70 (-0.34), NFLX: 101.58 (+3.65), SPLS: 9.60 (-0.27), UA: 84.00 (+0.91), AMZN: 575.14 (-2.35), NKE: 61.26 (-0.21), GILD: 87.21 (-0.62), WMT: 66.78 (+0.64), AAPL: 103.01 (+1.51)
The Simple Way I Search for the Next Hit Stock
Steve Symington, Andrés Cardenal, and Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 10:22AM CST
Where in the world is the next hit stock? Image source: The Motley Fool. With the broader stock market suffering a steep pullback so far in 2016, now is a great time for long-term investors to put their hard-earned money to work. But how can you...
UA: 84.00 (+0.91), EBAY: 24.41 (+0.47), NKE: 61.26 (-0.21), GILD: 87.21 (-0.62)
Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 8:00AM CST
SOURCE: REGULUS THERAPEUTICS. Gilead Sciences is racking up billions of dollars in sales of its hepatitis C drugs every quarter, but competitors are angling for market share, and that has investors nervous that Gilead Sciences' revenue in the...
GILD: 87.21 (-0.62), MRK: 52.08 (-0.02), RGLS: 7.22 (+0.03), ABBV: 56.15 (+0.22), BMY: 64.71 (-0.29)
Deutsche Bank:The Nutcracker Suite?
The Nattering Naybob - at Seeking Alpha - Fri Feb 19, 1:27PM CST
TSLA: 201.04 (+5.30), INTC: 30.63 (+0.05), GOOG: 710.89 (-1.53), SLB: 74.83 (-0.02), VTI: 102.07 (+0.35), SPY: 200.43 (+0.65), JPM: 60.05 (+0.09), EOG: 71.41 (+2.16), CAT: 72.84 (+1.09), MSFT: 52.03 (-0.32), CSCO: 26.80 (-0.07), DVY: 79.36 (+0.69), FB: 108.39 (-1.19), PFE: 29.71 (-0.18), COP: 41.12 (+2.56), WFC: 50.11 (+0.34), CSX: 25.23 (+0.33), GILD: 87.21 (-0.62), MCD: 117.18 (+0.49), CVX: 87.93 (+0.40), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), KMI: 18.52 (-0.38), GE: 30.46 (+0.24), F: 13.59 (+0.05), UNG: 5.93 (+0.14), FCX: 9.74 (+0.63), C: 42.83 (unch), XOM: 82.29 (-0.11), SBUX: 58.70 (-0.34), YHOO: 33.86 (+0.98), JNJ: 106.50 (-0.15), T: 37.93 (-0.06), IBM: 137.80 (unch), CHK: 5.08 (+0.81), CMG: 529.00 (+4.71), DIA: 170.02 (+0.67), OIL: 5.17 (+0.20), IVE: 88.22 (+0.39), LINE: 1.00 (+0.41), AAPL: 103.01 (+1.51), UNP: 80.50 (+0.49), XLE: 60.96 (+0.58), BHI: 46.20 (-0.35), KO: 44.11 (+0.15), AMZN: 575.14 (-2.35), USO: 9.65 (+0.40), DIS: 98.48 (-0.34), BAC: 13.54 (+0.04), NFLX: 101.58 (+3.65), PG: 83.49 (+0.65), VZ: 51.81 (-0.08)
A Yen For Yuan?
The Nattering Naybob - at Seeking Alpha - Fri Feb 19, 12:48PM CST
TSLA: 201.04 (+5.30), INTC: 30.63 (+0.05), GOOG: 710.89 (-1.53), SLB: 74.83 (-0.02), VTI: 102.07 (+0.35), SPY: 200.43 (+0.65), JPM: 60.05 (+0.09), EOG: 71.41 (+2.16), CAT: 72.84 (+1.09), MSFT: 52.03 (-0.32), CSCO: 26.80 (-0.07), DVY: 79.36 (+0.69), FB: 108.39 (-1.19), PFE: 29.71 (-0.18), COP: 41.12 (+2.56), WFC: 50.11 (+0.34), CSX: 25.23 (+0.33), GILD: 87.21 (-0.62), MCD: 117.18 (+0.49), CVX: 87.93 (+0.40), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), KMI: 18.52 (-0.38), GE: 30.46 (+0.24), F: 13.59 (+0.05), UNG: 5.93 (+0.14), FCX: 9.74 (+0.63), C: 42.83 (unch), XOM: 82.29 (-0.11), SBUX: 58.70 (-0.34), YHOO: 33.86 (+0.98), JNJ: 106.50 (-0.15), T: 37.93 (-0.06), IBM: 137.80 (unch), CHK: 5.08 (+0.81), CMG: 529.00 (+4.71), DIA: 170.02 (+0.67), OIL: 5.17 (+0.20), IVE: 88.22 (+0.39), LINE: 1.00 (+0.41), AAPL: 103.01 (+1.51), UNP: 80.50 (+0.49), XLE: 60.96 (+0.58), BHI: 46.20 (-0.35), KO: 44.11 (+0.15), AMZN: 575.14 (-2.35), USO: 9.65 (+0.40), DIS: 98.48 (-0.34), BAC: 13.54 (+0.04), NFLX: 101.58 (+3.65), PG: 83.49 (+0.65), VZ: 51.81 (-0.08)
Last Month's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 7:00AM CST
Source: Unsplash via Pixabay. February proved to be another roller-coaster month for investors. The S&P 500 cratered in the first few trading days of the month, shedding more than 5.5% of its value at its lowest point, but then it came...
AGN: 288.67 (-0.95), GILD: 87.21 (-0.62), XLV: 67.41 (-0.16)
Facebook, Starbucks, Schlumberger Lead Week’s Insider Trades
at Investor's Business Daily - Fri Mar 04, 5:15PM CST
Top brass from Facebook (FB), Starbucks (SBUX), Schlumberger (SLB) and Antero Resources (AR) were among those who made notable insider trades disclosed this week. Facebook Chris Cox, the social media giant's chief product officer, has sold 15,600...
SBUX: 58.70 (-0.34), AR: 22.89 (-1.00), GILD: 87.21 (-0.62), FB: 108.39 (-1.19), PANW: 150.97 (-1.05), SLB: 74.83 (-0.02)
Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
Business Wire - Fri Mar 04, 5:00PM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has elected to settle its conversion obligations in connection with any 1.625% Senior Convertible Notes due 2016 (the "Notes"
submitted for conversion on or after February 1, 2016 entirely in cash. GILD: 87.21 (-0.62), WFC: 50.11 (+0.34)
Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
Business Wire - Fri Mar 04, 3:00PM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 36th Annual Health Care Conference in Boston.
GILD: 87.21 (-0.62)
What Does Trump's Healthcare Plan Mean for Investors?
Arpita Dutt - Zacks Investment Research - Fri Mar 04, 10:57AM CST
The pharma industry has always stood strongly against attempts to legalize drug re-importation.
BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14), REGN: 403.82 (+1.88)
Another Threat To Gilead's HCV Prices Has Emerged
Shock Exchange - Seeking Alpha - Fri Mar 04, 6:40AM CST
(click to enlarge) NY Attorney General Eric Schneiderman. Source: NY Daily News From Hillary Clinton to Bernie Sanders, politicians brought up the issue of price-gouging by pharmaceutical companies. Many have been reacting to complaints by...
GILD: 87.21 (-0.62)
Gilead: Why The HCV Bull Case Is Bull
Bryan Boulden - at Seeking Alpha - Thu Mar 03, 8:37AM CST
GILD: 87.21 (-0.62)
Chronic Stable Angina Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Gilead Sciences, Lacer, Tasly Pharmaceuticals - Research and Markets
Business Wire - Thu Mar 03, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/23w5kc/chronic_stable) has announced the addition of the "Chronic Stable Angina Global Clinical Trials Review, H1, 2016" report to their offering. The clinical trial report, Chronic Stable Angina Global Clinical Trials Review, H1, 2016" provides an overview of Chronic Stable Angina clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Stable Angina. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered:
GILD: 87.21 (-0.62)
The Zacks Analyst Blog Highlights: Gilead, Amgen, Baxalta, PTC Therapeutics and Cara Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead, Amgen, Baxalta, PTC Therapeutics and Cara Therapeutics
CARA: 5.39 (-0.25), GILD: 87.21 (-0.62), PTCT: 6.06 (-0.04), AMGN: 145.98 (+0.14), BXLT: 39.47 (+0.17)
Dividend Growth Portfolio: February Update
The Dividend Bro - at Seeking Alpha - Thu Mar 03, 7:57AM CST
MMM: 160.07 (+0.69), GE: 30.46 (+0.24), XOM: 82.29 (-0.11), O: 58.16 (-0.86), VTR: 56.75 (+0.04), LUV: 41.50 (-0.53), PEP: 100.00 (+0.84), SBUX: 58.70 (-0.34), T: 37.93 (-0.06), JNJ: 106.50 (-0.15), V: 73.90 (-0.01), JPM: 60.05 (+0.09), TGT: 81.13 (+1.42), ABBV: 56.15 (+0.22), MSFT: 52.03 (-0.32), AAPL: 103.01 (+1.51), CSCO: 26.80 (-0.07), MA: 90.05 (+0.31), KO: 44.11 (+0.15), COP: 41.12 (+2.56), MO: 62.98 (+0.75), BA: 121.07 (+1.46), PM: 94.49 (+1.23), GILD: 87.21 (-0.62), CVS: 99.28 (-0.10), PE: 19.50 (+0.97), PG: 83.49 (+0.65), CVX: 87.93 (+0.40), VZ: 51.81 (-0.08), GIS: 60.20 (+0.41), AFL: 61.03 (+0.05)
Biotech Stock Roundup: Gilead HIV Drug Approved, Baxalta in Immuno-Oncology Deal
Arpita Dutt - Zacks Investment Research - Wed Mar 02, 1:35PM CST
Major biotech stocks were up last week while companies like Gilead (GILD) provided positive regulatory updates.
CARA: 5.39 (-0.25), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), ALXN: 144.46 (-1.39), PTCT: 6.06 (-0.04), AMGN: 145.98 (+0.14), BXLT: 39.47 (+0.17)
Q4 2015 Earnings Season Review - The Corporate Revenue Recession Deepens
ESTMZ - Wed Mar 02, 11:32AM CST
The fourth quarter earnings season for S&P 500 companies is officially wrapping up. The season started out on a sour note in January, with turbulent US markets, currency headwinds, plunging oil prices and a weakening Chinese economy all plaguing...
SPY: 200.43 (+0.65), GILD: 87.21 (-0.62), FB: 108.39 (-1.19), GOOGL: 730.22 (-1.37)
Biogen and Other Biotech Stocks Are About to Rally, These 3 Charts Show
at The Street - Sun Feb 21, 2:05PM CST
Biotech stocks have been hit hard since last summer, but comprehensive technical analysis shows they'll bounce soon. Here's how you can profit.
BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Is Big Pharma Evil?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Feb 21, 1:06PM CST
Big Pharma has been making a lot of unfortunate headlines lately, especially after Turing Pharmaceuticals' debacle surrounding pricing of Daraprim. Having once been a reasonably respected sector, recent studies have shown that in America, pharma is...
JNJ: 106.50 (-0.15), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Better Buy: Gilead Sciences Inc. vs. Amgen Inc.
Brian Feroldi, The Motley Fool - Motley Fool - Sun Feb 21, 9:04AM CST
Photo by Ano Lobb / Flickr Creative Commons. Gilead Sciences and Amgen have both been stellar investments for their long-term shareholders. Each has put up returns that have utterly smashed the S&P 500 over the past five, 10, and 20...
GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14)
5 Ways to Spot Awe-Inspiring Growth Stocks
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 5:01PM CST
SOURCE: FLICKR USER TAXCREDITS.NET. The never-ending quest of growth investors is to find and invest in revolutionary companies early on, but because there are thousands of publicly traded companies to choose from, it can be pretty tough figuring...
SBUX: 58.70 (-0.34), NFLX: 101.58 (+3.65), SPLS: 9.60 (-0.27), UA: 84.00 (+0.91), AMZN: 575.14 (-2.35), NKE: 61.26 (-0.21), GILD: 87.21 (-0.62), WMT: 66.78 (+0.64), AAPL: 103.01 (+1.51)
The Simple Way I Search for the Next Hit Stock
Steve Symington, Andrés Cardenal, and Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 10:22AM CST
Where in the world is the next hit stock? Image source: The Motley Fool. With the broader stock market suffering a steep pullback so far in 2016, now is a great time for long-term investors to put their hard-earned money to work. But how can you...
UA: 84.00 (+0.91), EBAY: 24.41 (+0.47), NKE: 61.26 (-0.21), GILD: 87.21 (-0.62)
Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 20, 8:00AM CST
SOURCE: REGULUS THERAPEUTICS. Gilead Sciences is racking up billions of dollars in sales of its hepatitis C drugs every quarter, but competitors are angling for market share, and that has investors nervous that Gilead Sciences' revenue in the...
GILD: 87.21 (-0.62), MRK: 52.08 (-0.02), RGLS: 7.22 (+0.03), ABBV: 56.15 (+0.22), BMY: 64.71 (-0.29)
Deutsche Bank:The Nutcracker Suite?
The Nattering Naybob - at Seeking Alpha - Fri Feb 19, 1:27PM CST
TSLA: 201.04 (+5.30), INTC: 30.63 (+0.05), GOOG: 710.89 (-1.53), SLB: 74.83 (-0.02), VTI: 102.07 (+0.35), SPY: 200.43 (+0.65), JPM: 60.05 (+0.09), EOG: 71.41 (+2.16), CAT: 72.84 (+1.09), MSFT: 52.03 (-0.32), CSCO: 26.80 (-0.07), DVY: 79.36 (+0.69), FB: 108.39 (-1.19), PFE: 29.71 (-0.18), COP: 41.12 (+2.56), WFC: 50.11 (+0.34), CSX: 25.23 (+0.33), GILD: 87.21 (-0.62), MCD: 117.18 (+0.49), CVX: 87.93 (+0.40), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), KMI: 18.52 (-0.38), GE: 30.46 (+0.24), F: 13.59 (+0.05), UNG: 5.93 (+0.14), FCX: 9.74 (+0.63), C: 42.83 (unch), XOM: 82.29 (-0.11), SBUX: 58.70 (-0.34), YHOO: 33.86 (+0.98), JNJ: 106.50 (-0.15), T: 37.93 (-0.06), IBM: 137.80 (unch), CHK: 5.08 (+0.81), CMG: 529.00 (+4.71), DIA: 170.02 (+0.67), OIL: 5.17 (+0.20), IVE: 88.22 (+0.39), LINE: 1.00 (+0.41), AAPL: 103.01 (+1.51), UNP: 80.50 (+0.49), XLE: 60.96 (+0.58), BHI: 46.20 (-0.35), KO: 44.11 (+0.15), AMZN: 575.14 (-2.35), USO: 9.65 (+0.40), DIS: 98.48 (-0.34), BAC: 13.54 (+0.04), NFLX: 101.58 (+3.65), PG: 83.49 (+0.65), VZ: 51.81 (-0.08)
A Yen For Yuan?
The Nattering Naybob - at Seeking Alpha - Fri Feb 19, 12:48PM CST
TSLA: 201.04 (+5.30), INTC: 30.63 (+0.05), GOOG: 710.89 (-1.53), SLB: 74.83 (-0.02), VTI: 102.07 (+0.35), SPY: 200.43 (+0.65), JPM: 60.05 (+0.09), EOG: 71.41 (+2.16), CAT: 72.84 (+1.09), MSFT: 52.03 (-0.32), CSCO: 26.80 (-0.07), DVY: 79.36 (+0.69), FB: 108.39 (-1.19), PFE: 29.71 (-0.18), COP: 41.12 (+2.56), WFC: 50.11 (+0.34), CSX: 25.23 (+0.33), GILD: 87.21 (-0.62), MCD: 117.18 (+0.49), CVX: 87.93 (+0.40), BRK.B: 137.97 (+1.13), BRK.A: 207,945.00 (+1,945.00), KMI: 18.52 (-0.38), GE: 30.46 (+0.24), F: 13.59 (+0.05), UNG: 5.93 (+0.14), FCX: 9.74 (+0.63), C: 42.83 (unch), XOM: 82.29 (-0.11), SBUX: 58.70 (-0.34), YHOO: 33.86 (+0.98), JNJ: 106.50 (-0.15), T: 37.93 (-0.06), IBM: 137.80 (unch), CHK: 5.08 (+0.81), CMG: 529.00 (+4.71), DIA: 170.02 (+0.67), OIL: 5.17 (+0.20), IVE: 88.22 (+0.39), LINE: 1.00 (+0.41), AAPL: 103.01 (+1.51), UNP: 80.50 (+0.49), XLE: 60.96 (+0.58), BHI: 46.20 (-0.35), KO: 44.11 (+0.15), AMZN: 575.14 (-2.35), USO: 9.65 (+0.40), DIS: 98.48 (-0.34), BAC: 13.54 (+0.04), NFLX: 101.58 (+3.65), PG: 83.49 (+0.65), VZ: 51.81 (-0.08)
